Glucoamylase (Amyloglucosidase / γ-Amylase)

Aspergillus niger (source organism for the fungal enzyme glucoamylase, EC 3.2.1.3, also called amyloglucosidase or gamma-amylase)
Evidence Level
Preliminary
3 Clinical Trials
7 Documented Benefits
1/5 Evidence Score

Digestive enzyme (EC 3.2.1.3, also known as amyloglucosidase or gamma-amylase) that hydrolyzes alpha-1,4 and alpha-1,6 glycosidic linkages in starch — releases glucose. Distinguishing from alpha-amylase, which cleaves only alpha-1,4. Aspergillus niger is the food-grade fungal source used commercially, so the enzyme is vegan-compatible. In a sucrase-deficient shrew model, oral recombinant glucoamylase increased blood glucose and starch digestion; that is animal evidence, and the enzyme used was a recombinant mammalian gut enzyme, not the Aspergillus glucoamylase sold in supplements. Separately, amyloglucosidase appears in some enzyme toothpastes and mouthrinses; that is a topical dental use, not a reason to swallow it. Honest framing: the evidence base is industrial, laboratory and animal, and no controlled human trial of glucoamylase on its own has been published.

Studied Dose No human trial has established a dose; digestive blends usually declare glucoamylase in activity units (AGU) and take it with meals.
Active Compound Glucoamylase EC 3.2.1.3 (amyloglucosidase, gamma-amylase); Aspergillus niger is the commercial food-grade fungal source; Rhizopus species are also used.

Benefits

CSID starch digestion

In a sucrase-deficient Suncus murinus shrew model of congenital sucrase-isomaltase deficiency, oral recombinant glucoamylase (ctMGAM) supplementation increased total blood glucose and quantitative starch digestion to glucose. This is animal evidence, and the enzyme given was a recombinant mammalian gut enzyme, not the Aspergillus glucoamylase in supplements. Congenital sucrase-isomaltase deficiency is a diagnosed medical condition managed by a specialist, and nothing here makes a digestive-enzyme blend a treatment for it.

α-1,4 + α-1,6 glycosidic bond hydrolysis (mechanism)

Glucoamylase hydrolyzes both alpha-1,4 and alpha-1,6 glycosidic linkages in starch — releases glucose. Distinguishing from alpha-amylase, which cleaves only alpha-1,4 linkages. In the test tube that means more complete starch breakdown than alpha-amylase alone, especially for amylopectin, the branched part of starch that carries alpha-1,6 branch points. Whether enough swallowed enzyme survives stomach acid and pepsin to matter at a real meal has not been measured in people.

Maltose hydrolysis to glucose

Hydrolyzes maltose and oligosaccharides to free glucose. That reaction is well described in the laboratory. It has not been shown to make up for the maltase your own gut lining produces, and a diagnosed brush border enzyme deficiency needs medical care rather than a digestive blend.

Maltase-glucoamylase brush border alternative

In theory a swallowed enzyme could carry out some of the same chemistry as mucosal MGAM (maltase-glucoamylase), an idea that comes from test-tube work and one shrew study. No human study has shown it replaces or compensates for missing brush border enzymes, and anyone with a diagnosed deficiency should be under specialist care.

Toothpaste enzyme system component (topical use, not a swallowed use)

Cross-application: amyloglucosidase is a key component of the LPO three-enzyme oral hygiene system (amyloglucosidase + glucose oxidase + LPO). In that system the enzyme releases glucose from starch, glucose oxidase converts the glucose into hydrogen peroxide, and lactoperoxidase uses the peroxide to make hypothiocyanite. This is a toothpaste and mouthrinse application, applied in the mouth and spat out, so it is not a reason to swallow glucoamylase. See the Lactoperoxidase entry for oral health applications.

Honest framing — limited human supplement evidence

Critical limitation: most evidence is in vitro, animal models, enzyme characterization, and industrial applications. No controlled human trial has tested swallowed glucoamylase on its own for digestion, and the published human work uses multi-enzyme blends containing it alongside several other enzymes, so nothing there can be credited to glucoamylase by itself. Treat it as one component of a blend rather than a headline ingredient.

Multi-enzyme formulation context

Glucoamylase typically appears in multi-enzyme digestive formulations alongside α-amylase, cellulase, hemicellulase, diastase, β-glucanase, invertase, lactase, and protease. Synergistic carbohydrate digestion across multiple substrate types — practical use is in combination, not as monotherapy.

Mechanism of action

1

α-1,4 + α-1,6 glycosidic bond hydrolysis

Hydrolyzes both α-1,4 and α-1,6 glycosidic linkages — distinguishing from α-amylase which cleaves only α-1,4. More complete starch digestion, particularly of amylopectin branch points.

2

Starch + maltodextrin to glucose conversion

Converts starch and maltodextrins efficiently to free glucose. Direct enzymatic conversion mechanism.

3

Brush border alternative pathway

A proposed alternative route to brush border MGAM for starch breakdown. This is a hypothesis from laboratory and animal work rather than something shown in people, and a diagnosed mucosal enzyme deficiency is a matter for a doctor.

4

Aspergillus niger fungal fermentation

Made by fermenting Aspergillus niger, the food-grade organism used commercially, so the enzyme is vegan-compatible. Rhizopus species are also used industrially.

5

LPO three-enzyme system H₂O₂ generation

In the LPO three-enzyme oral hygiene system, amyloglucosidase generates glucose from polyglucans. Glucose oxidase then converts glucose to H₂O₂, which LPO uses for hypothiocyanite production. Cascade-driven mechanism for sustained low-level antimicrobial activity.

6

Local GI lumen activity (no systemic absorption)

Acts locally in the gut, so no systemic absorption is needed. The real open question is different: a swallowed enzyme has to get past stomach acid and pepsin with useful activity left, and how much survives in people has not been measured.

Clinical trials

1
Animal study: sucrase-deficient shrew model (not a clinical trial)

Animal study in shrews, not a clinical trial. Nichols BL et al. 2017, J Pediatr Gastroenterol Nutr 65(2):e35-e42, doi:10.1097/MPG.0000000000001561.

Not applicable. Sucrase-deficient Suncus murinus shrews, an animal model of congenital sucrase-isomaltase deficiency. No people took part.

In sucrase-deficient Suncus murinus shrews, an animal model of congenital sucrase-isomaltase deficiency, oral recombinant glucoamylase (M20, ctMGAM) raised total blood glucose and starch digestion to glucose. Two limits matter: the subjects were shrews, and M20 is a recombinant form of the mammalian gut enzyme, not the Aspergillus glucoamylase sold in digestive blends.

2
Not a clinical trial: laboratory characterization of the human brush border enzyme

CtMGAM rapidly hydrolyzes maltotetraose and maltopentaose to glucose.

Not applicable. A laboratory study of enzyme activity on maltodextrins, with no participants.

This is a laboratory observation about ctMGAM, the C-terminal subunit of the human brush border enzyme, and no reference for it is given anywhere on this page. It involved no people and no animals, and it describes the enzyme the body makes rather than a swallowed fungal enzyme.

3
Not a clinical trial: animal feed and industrial literature

Animal feed and industrial application studies (and others).

Not applicable. Animal feed and industrial processing studies rather than a clinical trial.

No specific studies are cited here. Feed and industrial processing work shows the enzyme breaks starch down under those conditions, which is not clinical evidence. The published supplementation work in the congenital sucrase-isomaltase deficiency setting was done in shrews, not in people.

Side effects and drug interactions

Common Potential side effects

Usually well tolerated as a food-grade fungal enzyme, though no controlled human safety study of glucoamylase on its own has been published.
Mild GI upset (rare; transient).
Allergic reactions: this is a fungal enzyme, and glucoamylase from Aspergillus niger is a recognized allergen in bakery workers who inhale enzyme powders. Anyone with a mold or Aspergillus allergy should be cautious.
Pregnancy/lactation: limited specific data.
Long-term safety: limited human supplementation data — most evidence industrial/animal/in vitro.
Diabetes: starch digestion enhancement may affect postprandial glucose — monitor blood sugar.

Important Drug interactions

Diabetes medications (insulin, metformin, sulfonylureas): releasing more glucose from starch can raise post-meal blood sugar, so monitor glycemia. Alpha-glucosidase inhibitors such as acarbose and miglitol are prescribed to slow this same starch-to-glucose step, so a glucoamylase supplement may work against them; ask your doctor before combining.
Most medications: none documented, though no interaction study of this enzyme has been carried out.
Other digestive enzymes: compatible (often combined).
Anticoagulants: no interactions documented.
Antibiotics: no documented interactions.

Frequently asked questions about Glucoamylase (Amyloglucosidase / γ-Amylase)

What is glucoamylase?

Glucoamylase is a digestive enzyme that breaks down starch and maltose into glucose, complementing amylase in carbohydrate digestion. It is a component of digestive-enzyme blends rather than a standalone supplement.

What is glucoamylase used for?

It helps complete the breakdown of carbohydrates, particularly the maltose left after amylase acts, supporting fuller digestion of starchy foods. It is normally sold inside a digestive-enzyme blend rather than on its own.

When should I take glucoamylase?

Take it with meals, especially carbohydrate-rich ones, as part of a digestive-enzyme blend, so it is present as starches are digested.

Is glucoamylase safe?

As a digestive enzyme it is generally well tolerated. People with enzyme allergies or digestive conditions should check with a doctor. Because its job is to release glucose from starch, anyone managing blood sugar or taking diabetes medication should watch how meals affect them.

What is the recommended dosage of Glucoamylase?

The clinically studied dose is No human trial has established a dose; digestive blends usually declare glucoamylase in activity units (AGU) and take it with meals. Always follow the product label and check with a healthcare provider for personal advice.

Is Glucoamylase safe, and does it have side effects?

For most healthy adults, Glucoamylase is well tolerated at studied doses. Reported effects can include: Usually well tolerated as a food-grade fungal enzyme, though no controlled human safety study of glucoamylase on its own has been published. Mild GI upset (rare; transient). It may also interact with some medications. Glucoamylase is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Glucoamylase interact with any medications?

Possible interactions include: Diabetes medications (insulin, metformin, sulfonylureas): releasing more glucose from starch can raise post-meal blood sugar, so monitor glycemia. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Glucoamylase?

NutraSmarts rates the evidence for Glucoamylase as Preliminary (1 out of 5). It is backed by 3 clinical trials and 3 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(3 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Ao Z, Quezada-Calvillo R, Sim L, Nichols BL, Rose DR, Sterchi EE, Hamaker BR Evidence of native starch degradation with human small intestinal maltase-glucoamylase (recombinant) FEBS Lett. 2007;581(13):2381-8. doi:10.1016/j.febslet.2007.04.035.PubMedUsed to support: In vitro study of a recombinant subunit of the human brush border enzyme maltase-glucoamylase degrading raw starch granules. It is about the enzyme the small intestine makes, studied in a tube, and the paper reports that fungal amyloglucosidase did not reproduce the same hydrolysis or granule erosion patterns, so it does not support a swallowed fungal enzyme supplement.
  2. Nichols BL, Baker SS, Quezada-Calvillo R Metabolic Impacts of Maltase Deficiencies J Pediatr Gastroenterol Nutr. 2018;66 Suppl 3:S24-S29. doi:10.1097/MPG.0000000000001955.PubMedUsed to support: Review of how deficiencies in the body's own mucosal maltase enzymes are classified and read from duodenal biopsy assays. It describes human gut physiology and inherited enzyme deficiencies; it is not a study of taking a glucoamylase supplement.
  3. Nichols BL, Avery SE, Quezada-Calvillo R, Kilani SB, Lin AH, Burrin DG, Hodges BE, Chacko SK, Opekun AR, Hindawy ME, Hamaker BR, Oda SI Improved Starch Digestion of Sucrase-deficient Shrews Treated With Oral Glucoamylase Enzyme Supplements J Pediatr Gastroenterol Nutr. 2017;65(2):e35-e42. doi:10.1097/MPG.0000000000001561.PubMedUsed to support: Preclinical study using sucrase-deficient shrews (model for human CSID) showing oral glucoamylase enzyme supplementation significantly improves starch digestion and absorption; the enzyme used was a recombinant mammalian maltase-glucoamylase subunit rather than the fungal glucoamylase in supplements, so it is suggestive animal work, not support for the product.